In TRAIL-resistant cell lines (9–11), TRAIL recruits TNF receptor 1 associated death domain protein (TRADD)/TNF receptor-associated factors (TRAFs) through the receptor DR4/DR5 receptor to activate the NF-κB pathway and promote cell proliferation, while activated NF-κB targeted and inhibited the caspase pathway, thereby inhibiting tumor cell apoptosis. This evidence concerns the gene TNFSF10 and neoplasm.